Physician profile
Todd Baldanza
NPI 1841261427
$5,788.27
in general payments reported to CMS, 2019-2025
27 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $83.58 · 2022: $157 · 2023: $1,301 · 2024: $1,665 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.76 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,324.68 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $918.73 | 2019-2025 | Enbrel, Evenity, Amjevita |
| Janssen Biotech, INC. | $630.35 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $577.31 | 2023-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $482.53 | 2020-2025 | |
| Radius Health, INC. | $215.22 | 2023-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $195.73 | 2023-2025 | Lupkynis |
| Sobi, INC | $180.06 | 2024-2025 | |
| Organon LLC | $147.38 | 2022-2025 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $144.18 | 2023-2025 | Strensiq |
| Pfizer INC. | $135.27 | 2023-2025 | |
| Sandoz INC. | $116.16 | 2024-2025 | Hyrimoz |
| Merck Sharp & Dohme LLC | $98.59 | 2024-2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $93.22 | 2023 | Orencia |
| Lilly USA, LLC | $80.88 | 2025 | Taltz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $67.50 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $66.17 | 2025 | Acthar |
| Corcept Therapeutics | $55.75 | 2025 | Korlym |
| Kiniksa Pharmaceuticals International, Plc | $50.10 | 2024 | Arcalyst |
| Genentech USA, INC. | $35.92 | 2025 | Actemra |
| Tersera Therapeutics LLC | $32.57 | 2024 | Quzyttir |
| Fresenius Kabi USA, LLC | $27.62 | 2023 | Idacio |
| Invivyd INC | $26.13 | 2025 | Pemgarda |
| Biocon Biologics INC | $23.54 | 2024 | Hulio |
| Inspire Medical Systems, INC. | $23.12 | 2025 | Inspire |
| Celgene Corporation | $21.20 | 2019 | |
| Kyowa Kirin, INC. | $18.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Baldanza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.